Long‐term outcome of insulin pump therapy: reduction of hypoglycaemia and impact on glycaemic control
- 28 April 2016
- journal article
- research article
- Published by Wiley in Diabetic Medicine
- Vol. 33 (10) , 1422-1426
Abstract
Aims: To determine the long‐term outcome of continuous subcutaneous insulin infusion (CSII) in Type 1 diabetes according to Catalan National Health Service indications.Methods: Retrospective observational study including 178 patients with Type 1 diabetes who started CSII treatment in our centre (2003–2008). All patients were followed in our CSII programme for outpatients for at least 5 years. Data on annual HbA1c levels were collected, and the main indication for starting CSII was analysed.Results: Twenty‐seven of 178 patients were excluded because of loss to follow‐up or withdrawal from CSII, thus 151 patients (aged 37.4 ± 10.5 years, 64% women) were analysed. The main indications for starting CSII were suboptimal metabolic control (60.9%), severe hypoglycaemia/hypoglycaemia unawareness (25.5%) and others (13.6%). HbA1c was 64 ± 13 mmol/mol (8.0 ± 1.2%) at the start of CSII and 62 ± 13 mmol/mol (7.8 ± 1.2%) after 5 years in the total cohort (P = 0.1). The severe hypoglycaemia rates were 0.66 ± 1.61 and 0.17 ± 0.42 episodes/patient/year (P < 0.001). In patients with suboptimal metabolic control, HbA1c decreased from 68 ± 12 mmol/mol (8.4 ± 1.1%) to 64 ± 14 mmol/mol (8.0 ± 1.3%) (P = 0.016), with 37.4% of those in this group having an HbA1c ≤ 58 mmol/mol (7.5%) after 5 years. In patients starting CSII due to severe hypoglycaemia the problem was considered resolved in 93%, and in 64% of those starting CSII because of suboptimal glycaemic control, HbA1c improved significantly.Conclusions: CSII therapy achieves and maintains its efficacy mainly in terms of reducing severe hypoglycaemia. In the whole group of patients, the reduction in HbA1c is transient and disappears after 5 years.Keywords
This publication has 14 references indexed in Scilit:
- Long-Term Efficacy of Insulin Pump Therapy on Glycemic Control in Adults with Type 1 Diabetes MellitusDiabetes Technology & Therapeutics, 2015
- Variations in the quality and sustainability of long‐term glycaemic control with continuous subcutaneous insulin infusionDiabetic Medicine, 2014
- Improved Metabolic Control in Pediatric Patients with Type 1 Diabetes: A Nationwide Prospective 12-Year Time Trends AnalysisDiabetes Technology & Therapeutics, 2014
- Insulin Pump—Long-Term Effects on Glycemic Control: An Observational Study at 10 Diabetes Clinics in SwedenDiabetes Technology & Therapeutics, 2013
- Continuous subcutaneous insulin infusion (CSII) 30 years later: still the best option for insulin therapyDiabetes/Metabolism Research and Reviews, 2009
- NICE guidance on continuous subcutaneous insulin infusion 2008: review of the technology appraisal guidanceDiabetic Medicine, 2009
- Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta‐analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusionDiabetic Medicine, 2008
- Establishing glycaemic control with continuous subcutaneous insulin infusion in children and adolescents with type 1 diabetes: experience of the PedPump Study in 17 countriesDiabetologia, 2008
- Efficacy of continuous subcutaneous insulin infusion in Type 1 diabetes: a 2‐year perspective using the established criteria for funding from a National Health ServiceDiabetic Medicine, 2007
- Defining and Reporting Hypoglycemia in DiabetesDiabetes Care, 2005